The Technical Analyst
Ascendis Pharma A/S [ASND]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Ascendis Pharma A/S Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-0.51% $140.17
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 7 935.64 mill |
| EPS: | -9.07 |
| P/E: | -15.45 |
| Earnings Date: | Apr 25, 2024 |
| SharesOutstanding: | 56.61 mill |
| Avg Daily Volume: | 0.356 mill |
| RATING 2024-04-19 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Sell | |
| DE: | Strong Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -15.45 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -2.63x |
| Company: PE -15.45 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 135.30 - 145.04 ( +/- 3.47%) |
| ATR Model: 14 days |
Forecast:
16:00 - $140.35
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $140.35
Forecast 2: 16:00 - $140.35
Forecast 3: 16:00 - $140.35
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $140.17 (-0.51% ) |
| Volume | 0.267 mill |
| Avg. Vol. | 0.356 mill |
| % of Avg. Vol | 75.14 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ASND
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $139.22 | N/A | Active |
|---|
ASND
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Latest Press Releases
2024-03-04 08:30:00 - Press Release
Ascendis Pharma To Participate In The Leerink Partners Global Biopharma Conference 2024
Copenhagen, denmark, march 04, 2024 (globe newswire) -- ascendis pharma a/s (nasdaq: asnd) today announced that company executives will participate in a fireside chat at the leerink partners global biopharma conference 2024 on monday, march 11, 2024 at 2:00 p.m. et in miami, florida.
2024-02-07 16:01:00 - Press Release
Ascendis Pharma Reports Fourth Quarter And Full Year 2023 Results
Copenhagen, denmark, feb. 07, 2024 (globe newswire) -- ascendis pharma a/s (nasdaq: asnd) today announced financial results for the fourth quarter and full year ended december 31, 2023 and provided a business update.
2024-02-07 08:30:00 - Press Release
Ascendis Pharma To Participate In The Oppenheimer 34th Annual Healthcare Life Sciences Conference
Copenhagen, denmark, feb. 07, 2024 (globe newswire) -- ascendis pharma a/s (nasdaq: asnd) today announced that company executives will participate in the oppenheimer 34th annual healthcare life sciences conference.
2024-01-31 16:15:00 - Press Release
Ascendis Pharma To Report Full Year 2023 Financial Results And Provide Business Update On February 7, 2024
Copenhagen, denmark, jan. 31, 2024 (globe newswire) -- ascendis pharma a/s (nasdaq: asnd) today announced it will report full year 2023 financial results and provide a business update on wednesday, february 7, 2024, after the close of the u.s. financial markets. ascendis pharma will also host a conference call and webcast on february 7, 2024, at 4:30 p.m. eastern time (et) to discuss 2023 financial results.
2024-01-31 16:01:00 - Press Release
Ascendis Pharma Launches 2nd Transcon™ Product: yorvipath® Now Available In Germany And Austria For Adults With Chronic Hypoparathyroidism
Copenhagen, denmark, jan. 31, 2024 (globe newswire) -- ascendis pharma a/s (nasdaq: asnd) today announced that yorvipath® (palopegteriparatide, developed as transcon pth), a parathyroid hormone (pth) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism, is now available in germany and austria. yorvipath is the second product developed with ascendis pharma's transcon technology platform to be launched commercially.
Latest News
2024-04-10 09:27:00 - Market Watch
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.
2024-03-08 08:36:05 - Zacks Investment Research
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
We have narrowed our search to five biotech stocks with strong potential for 2024. These are MOR, LEGN, ASND, EXEL and EXAS.
2024-02-15 13:00:19 - Zacks Investment Research
Ascendis Pharma A/S (ASND) is a Great Momentum Stock: Should You Buy?
Does Ascendis Pharma A/S (ASND) have what it takes to be a top stock pick for momentum investors? Let's find out.
2024-02-15 10:40:28 - Zacks Investment Research
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?
Here is how Ascendis Pharma A/S (ASND) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.
2024-02-07 22:18:05 - Seeking Alpha
Ascendis Pharma A/S (ASND) Q4 2023 Earnings Call Transcript
2024-02-06 09:51:22 - Zacks Investment Research
Why Earnings Season Could Be Great for Ascendis Pharma (ASND)
Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
2024-01-31 16:15:00 - GlobeNewsWire
Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024
COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report full year 2023 financial results and provide a business update on Wednesday, February 7, 2024, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and webcast on February 7, 2024, at 4:30 p.m. Eastern Time (ET) to discuss 2023 financial results.
2023-11-07 20:22:08 - Seeking Alpha
Ascendis Pharma A/S (ASND) Q3 2023 Earnings Call Transcript
Ascendis Pharma A/S (ASND) Q3 2023 Results Conference Call November 7, 2023 4:30 PM ET Company Participants Timothy Lee - Investor Relations Jan Mikkelsen - President and Chief Executive Officer Scott Smith - Executive Vice President and Chief Financial Officer Conference Call Participants Paul Choi - Goldman Sachs Joseph Schwartz - Leerink Partners Yaron Werber - TD Cowen Li Watsek - Cantor Fitzgerald Leland Gershell - Oppenheimer Operator Hello, and welcome to Ascendis Pharma Third Quarter 2023 Earnings Conference Call and Webcast. Following the prepared remarks, there will be a question-and-answer period, instructions will be given at that time.
2023-10-31 08:30:00 - GlobeNewsWire
Ascendis Pharma Announces Timing of Third Quarter 2023 Financial Results and TransCon PTH NDA Resubmission
• Third Quarter financial results and business update conference call to be held on November 7, 2023 • Resubmission of TransCon PTH NDA for adults with hypoparathyroidism expected before mid-November 2023 COPENHAGEN, Denmark, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report third quarter 2023 financial results and provide a business update on Tuesday, November 7, 2023, after the close of the U.S. financial markets. In addition, Ascendis Pharma announced that it plans to resubmit its NDA for TransCon PTH for adults with hypoparathyroidism to the FDA before mid-November 2023.
2023-10-26 11:23:40 - Zacks Investment Research
Ascendis Pharma A/S (ASND) Loses -8.26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Ascendis Pharma A/S (ASND) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.